Global Fluoxetine Market Size to Reach USD 1,367.46 Million by 2031 | CAGR of 3.8%
Category : Healthcare | Published Date : Jun 2024 | Type : Press Release
Fluoxetine Market Definition & Overview :
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant drug, used for the treatment of mental health disorders. It helps by increasing serotonin levels in the brain, which reduces anxiety and improves appetite and sleep.
Consegic Business Intelligence analyzes that the Global Fluoxetine Market size was valued at USD 980.47 Million in 2022, projected to grow by USD 1,011.63 Million in 2023, and is expected to register a CAGR of 3.8% to reach USD 1,367.46 Million by 2031.
This report comprises Fluoxetine Market Share, Size & Industry Analysis, By Form (Capsule, Tablet, and Solution), By Application(Depression, Anxiety Disorders, Panic Attacks, and Others), By End-User(Clinic, Hospital, and Others), By Region(North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa), and Forecast 2023-2031.
This report contains detailed information on Fluoxetine Market Growth Rate, Opportunities, Trends, Value, Segmentation, Geographical Coverage, Company Profile, In-depth Expert Analysis, Revenue Forecast, Competitive Landscape, Growth Factors, Restraint or Challenges, Environment & Regulatory Landscape, PESTLE Analysis, PORTER Analysis, Key Technology Landscape, Value Chain Analysis, and Cost Analysis.
As per the report analysis, the rising mental health disorders in the modern era and the awareness of these diseases tend to surge the fluoxetine market growth. This antidepressant drug has several applications including the treatment of alcoholism, sleep disorders, headaches, and posttraumatic stress disorder among others.
Segmental Analysis :
The Fluoxetine Market is segmented into four major segments based on form, application, end-user, and region.
Based on form, the market is trifurcated into capsules, tablets, and solutions.
- The capsule segment held the largest market share of 52.50% in 2022 and is also anticipated to grow at the fastest CAGR from 2023 to 2031, as it is easy and convenient to consume and cannot be crushed or split.
Based on application, the market is segregated into depression, anxiety disorders, panic attacks, and others.
- In 2022, the depression segment held the highest market share due to an increase in stress, social isolation, and economic instability.
- However, the anxiety segment is anticipated to grow at the fastest CAGR from 2023 to 2031, because of a rise in anxiety disorders in adults.
Based on end-users, the market is categorized into clinics, hospitals, and others.
- The clinics segment accounted for the highest market share in 2022 and is also expected to register the fastest CAGR over the forecasted period, as they provide various facilities like therapy, medical attention, and support groups.
By region, the market is segregated into regions including North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
- In the North American region, the US alone accounted for 66.30% market share out of the USD 374.05 million in 2022, due to a rise in mental health disorders including anxiety, depression, eating disorders, and paranoia among others.
- The Asia-Pacific region is anticipated to grow at the fastest CAGR of 4.2% during the forecasted period, because of the growing population having age-related mental health disorders.
| Report Attributes | Report Details |
| By Form | Capsule, Tablet, and Solution |
| By Application | Depression, Anxiety Disorders, Panic Attacks, and Others |
| By End-User | Clinic, Hospital, and Others |
| By Region | North America(U.S., Canada, Mexico) Europe(U.K., Germany, France, Spain, Italy, Russia, Benelux, Rest of Europe) APAC(China, South Korea, Japan, India, Australia, ASEAN, Rest of Asia-Pacific) Middle East & Africa(GCC, Turkey, South Africa, Rest of MEA) LATAM(Brazil, Argentina, Chile, Rest of LATAM) |
Top Key Players & Competitive Landscape :
The competitive landscape encompasses major innovators, aftermarket service providers, industry giants, and niche players, all of which are thoroughly examined by Consegic Business Intelligence in terms of their strengths, weaknesses, and value-addition potential. Additionally, this report includes detailed profiles of key players, market share analysis, mergers and acquisitions, resulting market fragmentation, and emerging partnership trends and dynamics.
List of prominent players in the Fluoxetine Industry :
- Aurobindo Pharma
- Alembic Pharmaceuticals Limited
- Cadila Pharmaceuticals
- Teva Pharmaceuticals USA, Inc.
- Par Pharmaceutical
- Dr. Reddy's Laboratories Limited
- Lannett
- Sun Pharmaceutical Industries Ltd.
- Alvogen
- Eli Lilly and Company
- Accord Healthcare
- Lupin Pharmaceuticals, Inc.
Recent Industry Developments :
- In April 2021, FDA approved the Lannett's fluoxetine oral solution.
- Lupin Pharmaceuticals, Inc. in February 2019, received FDA approval for Fluoxetine Tablets USP to market a generic version of Alvogen Fluoxetine Tablets, 60mg.
